Favorable safety and efficacy of duvelisib maintenance after autologous stem cell transplant in peripheral T-cell lymphomas
Clinical Lymphoma, Myeloma & Leukemia
· Elsevier
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитирование
Favorable safety and efficacy of duvelisib maintenance after autologous stem cell transplant in peripheral T-cell lymphomas. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026040000?dgcid=rss_sd_all
Favorable safety and efficacy of duvelisib maintenance after autologous stem cell transplant in peripheral T-cell lymphomas. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026040000?dgcid=rss_sd_all
“Favorable safety and efficacy of duvelisib maintenance after autologous stem cell transplant in peripheral T-cell lymphomas.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article88836,
title = {Favorable safety and efficacy of duvelisib maintenance after autologous stem cell transplant in peripheral T-cell lymphomas},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026040000?dgcid=rss_sd_all}
}